-
1
-
-
0035286778
-
Caco-2 monolayers in experimental and theoretical predictions of drug transport
-
DOI 10.1016/S0169-409X(00)00128-9, PII S0169409X00001289
-
Artursson P, Palm K, and Luthman K (2001) Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46:27-43. (Pubitemid 33653412)
-
(2000)
Advanced Drug Delivery Reviews
, vol.46
, Issue.1-3
, pp. 27-43
-
-
Artursson, P.1
Palm, K.2
Luthman, K.3
-
3
-
-
0032864111
-
Studies on the substrate specificity of human intestinal UDP-glucuronosyltransferases 1A8 and 1A10
-
Cheng Z, Radominska-Pandya A, and Tephly TR (1999) Studies on the substrate specificity of human intestinal UDP-glucuronosyltransferases 1A8 and 1A10. Drug Metab Dispos 27:1165-1170.
-
(1999)
Drug Metab Dispos
, vol.27
, pp. 1165-1170
-
-
Cheng, Z.1
Radominska-Pandya, A.2
Tephly, T.R.3
-
4
-
-
74549132748
-
Interindividual variability in hepatic drug glucuronidation: Studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system
-
Court MH (2010) Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Met Rev 42:209-224.
-
(2010)
Drug Met Rev
, vol.42
, pp. 209-224
-
-
Court, M.H.1
-
5
-
-
34248596908
-
Bazedoxifene acetate dose proportionality in healthy, postmenopausal women
-
Ermer J, McKeand W, Sullivan P, Parker V, and Orczyk G (2003) Bazedoxifene acetate dose proportionality in healthy, postmenopausal women. Clin Pharmacol Ther 73:P46.
-
(2003)
Clin Pharmacol Ther
, vol.73
-
-
Ermer, J.1
McKeand, W.2
Sullivan, P.3
Parker, V.4
Orczyk, G.5
-
6
-
-
61549094100
-
Bazedoxifene for the prevention of postmenopausal osteoporosis
-
Gennari L, Merlotti D, De Paola V, Martini G, and Nuti R (2008) Bazedoxifene for the prevention of postmenopausal osteoporosis. Ther Clin Risk Manag 4:1229-1242.
-
(2008)
Ther Clin Risk Manag
, vol.4
, pp. 1229-1242
-
-
Gennari, L.1
Merlotti, D.2
De Paola, V.3
Martini, G.4
Nuti, R.5
-
7
-
-
34249055240
-
Selective estrogen receptor modulators for postmenopausal osteoporosis: Current state of development
-
Gennari L, Merlotti D, Valleggi F, Martini G, and Nuti R (2007) Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging 24:361-379.
-
(2007)
Drugs Aging
, vol.24
, pp. 361-379
-
-
Gennari, L.1
Merlotti, D.2
Valleggi, F.3
Martini, G.4
Nuti, R.5
-
10
-
-
3042681890
-
Disposition mechanisms of raloxifene in the human intestinal Caco-2 model
-
Jeong EJ, Lin H, and Hu M (2004) Disposition mechanisms of raloxifene in the human intestinal Caco-2 model. J Pharmacol Exp Ther 310:376-385.
-
(2004)
J Pharmacol Exp Ther
, vol.310
, pp. 376-385
-
-
Jeong, E.J.1
Lin, H.2
Hu, M.3
-
11
-
-
18844431909
-
Species- and disposition model-dependent metabolism of raloxifene in gut and liver: Role of UGT1A10
-
Jeong EJ, Liu Y, Lin H, and Hu M (2005) Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab Dispos 33:785-794.
-
(2005)
Drug Metab Dispos
, vol.33
, pp. 785-794
-
-
Jeong, E.J.1
Liu, Y.2
Lin, H.3
Hu, M.4
-
12
-
-
67349207750
-
Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX
-
Kanis JA, Johansson H, Oden A, and McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049-1054.
-
(2009)
Bone
, vol.44
, pp. 1049-1054
-
-
Kanis, J.A.1
Johansson, H.2
Oden, A.3
McCloskey, E.V.4
-
13
-
-
0036266936
-
Characterization of raloxifene glucuronidation in vitro: Contribution of intestinal metabolism to presystemic clearance
-
Kemp DC, Fan PW, and Stevens JC (2002) Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30:694-700.
-
(2002)
Drug Metab Dispos
, vol.30
, pp. 694-700
-
-
Kemp, D.C.1
Fan, P.W.2
Stevens, J.C.3
-
14
-
-
23844531615
-
Bazedoxifene acetate: A selective estrogen receptor modulator with improved selectivity
-
Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, and Lyttle CR (2005) Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 146:3999-4008.
-
(2005)
Endocrinology
, vol.146
, pp. 3999-4008
-
-
Komm, B.S.1
Kharode, Y.P.2
Bodine, P.V.3
Harris, H.A.4
Miller, C.P.5
Lyttle, C.R.6
-
15
-
-
35248855591
-
Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis
-
Lewiecki EM (2007) Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis. Expert Opin Investig Drugs 16:1663-1672.
-
(2007)
Expert Opin Investig Drugs
, vol.16
, pp. 1663-1672
-
-
Lewiecki, E.M.1
-
17
-
-
41849138667
-
Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study
-
Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G, and Delmas PD (2008) Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 23:525-535.
-
(2008)
J Bone Miner Res
, vol.23
, pp. 525-535
-
-
Miller, P.D.1
Chines, A.A.2
Christiansen, C.3
Hoeck, H.C.4
Kendler, D.L.5
Lewiecki, E.M.6
Woodson, G.7
Levine, A.B.8
Constantine, G.9
Delmas, P.D.10
-
18
-
-
67650591016
-
Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9 and 1A10
-
Mizuma T (2009) Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9 and 1A10. Int J Pharm 378:140-141.
-
(2009)
Int J Pharm
, vol.378
, pp. 140-141
-
-
Mizuma, T.1
-
19
-
-
0037255847
-
Pharmacokinetics of selective estrogen receptor modulators
-
DOI 10.2165/00003088-200342040-00004
-
Morello KC, Wurz GT, and DeGregorio MW (2003) Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 42:361-372. (Pubitemid 36433876)
-
(2003)
Clinical Pharmacokinetics
, vol.42
, Issue.4
, pp. 361-372
-
-
Morello, K.C.1
Wurz, G.T.2
DeGregorio, M.W.3
-
20
-
-
34248598671
-
Absolute bioavailability of bazedoxifene acetate in healthy postmenopausal women
-
Patat A, McKeand W, Baird Bellaire S, Ermer J, and LeCoz F (2003) Absolute bioavailability of bazedoxifene acetate in healthy postmenopausal women. Clin Pharmacol Ther 73:P43.
-
(2003)
Clin Pharmacol Ther
, vol.73
-
-
Patat, A.1
McKeand, W.2
Baird Bellaire, S.3
Ermer, J.4
LeCoz, F.5
-
21
-
-
19544386490
-
Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women
-
DOI 10.1097/01.AOG.0000163253.27610.b9
-
Ronkin S, Northington R, Baracat E, Nunes MG, Archer DF, Constantine G, and Pickar JH (2005) Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 105:1397-1404. (Pubitemid 40734275)
-
(2005)
Obstetrics and Gynecology
, vol.105
, Issue.6
, pp. 1397-1404
-
-
Ronkin, S.1
Northington, R.2
Baracat, E.3
Nunes, M.G.4
Archer, D.F.5
Constantine, G.6
Pickar, J.H.7
-
22
-
-
56549092475
-
Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: Results from a 3-year, randomized, placebo-, and active-controlled clinical trial
-
Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, and Chines AA (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23:1923-1934.
-
(2008)
J Bone Miner Res
, vol.23
, pp. 1923-1934
-
-
Silverman, S.L.1
Christiansen, C.2
Genant, H.K.3
Vukicevic, S.4
Zanchetta, J.R.5
De Villiers, T.J.6
Constantine, G.D.7
Chines, A.A.8
-
23
-
-
34248585154
-
Bazedoxifene: A third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis
-
Stump AL, Kelley KW, and Wensel TM (2007) Bazedoxifene: a third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis. Ann Pharmacother 41:833-839.
-
(2007)
Ann Pharmacother
, vol.41
, pp. 833-839
-
-
Stump, A.L.1
Kelley, K.W.2
Wensel, T.M.3
|